Hematologic Diseases: Clinical Trials

23 trials for Hematologic Diseases, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

23 enrolling by invitation. 23 Phase 2, 7 Phase 1, 4 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 223Enrolling by invitation 23
Phase 17Enrolling by invitation 7
Phase 34Enrolling by invitation 4

Follow Hematologic Diseases: new trials by email Literature Review of Hematologic Diseases trials Research Report on Hematologic Diseases

Trials (filtered) newest first · largest first

All 23 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Base-Edited Hematopoietic Stem/Progenitor Cell Gene Therapy for Treatment of CXCR4-WHIM
Busulfan, Palifermin, Plerixafor - WHIM, Warts
Phase 1 / Phase 2Enrolling by invitationNational Institute of Allergy and Infectious Diseases (NIAID)102026-10-212026-10-27
Homoharringtonine, Lisaftoclax, and Azacitidine for AML After Venetoclax-Based Therapy Failure
Lisaftoclax (APG-2575), homoharringtonine, Azacitidine (AZA) - Acute Myeloid Leukemia (AML)
Phase 2Enrolling by invitationGuangdong Second Provincial General Hospital732026-09-012026-09-10
Rituximab+ Zanubrutinib for Patients With Hairy Cell Leukemia and Hairy Cell Variant
Zanubrutinib - Hairy Cell Leukemia, Hairy Cell Leukemia Variant
Phase 2Enrolling by invitationBnai Zion Medical Center122026-06-012026-07-08
Adding Asciminib to Usual Treatment for Adults With Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Acute Lymphoblastic Leukemia
Induction Phase, Re-Induction Phase, Post-Remission - Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia, CD19+ Acute Leukemia
Phase 2Enrolling by invitationSWOG Cancer Research Network552026-04-132026-10-05
VEN+IDAC vs IDAC in AML
Ventoclax, Cytarabine - AML (Acute Myelogenous Leukemia)
Phase 2 / Phase 3Enrolling by invitationGuangdong Second Provincial General Hospital2322026-04-012026-04-17
HVA in the Treatment of Mixed-Phenotype Acute Leukemia(MPAL).
HVA - Newly Diagnosed Mixed Phenotype Acute Leukemia (MPAL)
Phase 2Enrolling by invitationGuangdong Second Provincial General Hospital402026-04-012026-04-08
Comparing the Efficacy of the LDA, LHAA, and DA Regimens in Young Adults With Low-Risk Acute Myeloid Leukemia Eligible for Intensive Chemotherapy
Lisaftoclax+daunorubicin+cytarabine, Lisaftoclax+homoharringtonine+cytarabine+aclarubicin, Daunorubicin+cytarabine - Acute Myeloid Leukemia, Lisaftoclax
Phase 2 / Phase 3Enrolling by invitationFirst Affiliated Hospital of Zhejiang University2672026-03-012026-06-16
Comparing the Efficacy of LDA, LHAA, and LA Regimens in Young Adults With Intermediate- and High-Risk Acute Myeloid Leukemia Eligible for Intensive Chemotherapy
Lisaftoclax+daunorubicin+cytarabine, Lisaftoclax+homoharringtonine+cytarabine+aclarubicin, Lisaftoclax+azacitidine - Acute Myeloid Leukemia (AML), Lisaftoclax
Phase 2 / Phase 3Enrolling by invitationFirst Affiliated Hospital of Zhejiang University4502026-03-012026-06-16
RVU120 Rollover Study
RVU120, Ruxolitinib - Advanced Solid Tumors, Acute Myeloid Leukaemia (AML)
Phase 2Enrolling by invitationRyvu Therapeutics SA142025-12-042026-09-17
Part B- G1X-CGD (Lentiviral Vector Transduced CD34+ Cells) in Patients With X-Linked Chronic Granulomatous Disease
Busulfan, Tocilizumab, Eltrombopag - Chronic Granulomatous Disease (CGD)
Phase 1 / Phase 2Enrolling by invitationNational Institute of Allergy and Infectious Diseases (NIAID)102025-09-102026-09-08
Effectiveness of Probiotics for the Prevention of Gastrointestinal Toxicity in Children With Leukemia
Lactobacillus casei, Lactobacillus rhamnosus, Bifidobacterium bifidum - Probiotics, Gastrointestinal Diseases
Phase 2Enrolling by invitationNational Institute of Pediatrics, Mexico1202025-02-012025-03-14
A Study of the Safety and Efficacy of Prime Editing (PM359) in Participants With p47phox Autosomal Recessive Chronic Granulomatous Disease (CGD )
PM359 - Chronic Granulomatous Disease, Granulomatous Disease, Chronic
Phase 1 / Phase 2Enrolling by invitationPrime Medicine, Inc.122024-10-172026-04-06
pCCLCHIM-p47 (Lentiviral Vector Transduced CD34 Plus Cells) in Patients With p47 Autosomal Recessive Chronic Granulomatous Disease (AR-CGD)
Cryopreserved Autologous CD34+ cells transduced with pCCLCHIM-p47 - p47, Autosomal Recessive
Phase 1 / Phase 2Enrolling by invitationNational Institute of Allergy and Infectious Diseases (NIAID)102024-06-252026-11-18
Venetoclax for Prevention of Differentiation Syndrom in Acute Promyelocytic Leukemia Patients
venetoclax - Acute Promyelocytic Leukemia
Phase 2 / Phase 3Enrolling by invitationThe First Affiliated Hospital of Soochow University982023-08-012024-08-09
International Treatment-extension Study in Adult Participants With Multiple Myeloma and Who Have Derived Clinical Benefit From Isatuximab
Isatuximab intravenous (IV), Cemiplimab (SAR439684), Dexamethasone - Plasma Cell Myeloma
Phase 2Enrolling by invitationSanofi702023-04-052026-10-15
Phase I Clinical Study of Haplo-HSCT Combined With Hypoxic 3D-Cultured Umbilical Cord MSC for the Treatment of SAA
3D hypoxia-preconditioned UC-MSC group, 2D UC-MSC group - Severe Aplastic Anemia (SAA), Severe Aplastic Anemia, Refractory
Phase 1 / Phase 2Enrolling by invitationChinese PLA General Hospital402022-08-012026-06-23
Donor-Derived Ex-Vivo Expanded Natural Killer Cell Infusions in Children and Young Adults With High Risk Acute Myeloid Leukemia Receiving Myeloablative HLA-Haploidentical Hematopoietic Cell Transplant
Donor-Derived Ex-Vivo Expanded Natural Killer Cell Infusions - Acute Myeloid Leukemia
Phase 2Enrolling by invitationMichael Pulsipher302021-08-242025-05-04
The BENeFiTS Trial in Beta Thalassemia Intermedia
Benserazide Only Product - Beta Thalassemia Intermedia, Sickle Cell Disease
Phase 1 / Phase 2Enrolling by invitationPhoenicia BioScience362020-10-052025-08-15
A Study for Participants Who Participated in Prior Clinical Studies of ASTX727 (Standard Dose)
ASTX727 - Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia
Phase 2Enrolling by invitationTaiho Oncology, Inc.3322019-09-302026-07-28
A Nationwide Phase 2 Trial of Patients With Smoldering and Active Multiple Myeloma (MM)
Carfilzomib, Lenalidomide, Dexamethasone - Multiple Myeloma, Smoldering Multiple Myeloma
Phase 2Enrolling by invitationLandspitali University Hospital802019-06-242019-08-16

Showing 20 of 23. Sign in to see all of them.

Narrower conditions

Leukemia, Myeloid, Acute (8)  ·  Granulomatous Disease, Chronic (4)  ·  Multiple Myeloma (3)  ·  Myelodysplastic Syndromes (3)  ·  Precursor Cell Lymphoblastic Leukemia-Lymphoma (3)  ·  Neoplasm, Residual (2)  ·  Agammaglobulinemia (1)  ·  Anemia, Aplastic (1)  ·  Anemia, Sickle Cell (1)  ·  Common Variable Immunodeficiency (1)  ·  Gastrointestinal Diseases (1)  ·  Granulomatous Disease, Chronic, Autosomal Recessive, Cytochrome B-Positive, Type I (1)  ·  Immunologic Deficiency Syndromes (1)  ·  Job Syndrome (1)  ·  Leukemia, Biphenotypic, Acute (1)

Broader conditions

Hemic and Lymphatic Diseases (23)  ·  Neoplasms (16)  ·  Neoplasms by Histologic Type (16)  ·  Immune System Diseases (13)  ·  Leukemia (13)  ·  Leukemia, Myeloid (9)  ·  Lymphoproliferative Disorders (9)  ·  Immunoproliferative Disorders (8)  ·  Pathologic Processes (8)  ·  Pathological Conditions, Signs and Symptoms (8)  ·  Lymphatic Diseases (7)  ·  Disease Attributes (6)  ·  Chronic Disease (5)  ·  Congenital, Hereditary, and Neonatal Diseases and Abnormalities (5)

Interventions

Azacitidine (2)  ·  Busulfan (2)  ·  Dexamethasone (2)  ·  Induction Chemotherapy (2)  ·  Lenalidomide (2)  ·  Opiate Substitution Treatment (2)  ·  carfilzomib (2)  ·  Cytarabine (1)  ·  Fibroblast Growth Factor 7 (1)  ·  Filgrastim (1)  ·  Genes (1)  ·  Homoharringtonine (1)  ·  Lisaftoclax (1)  ·  Maintenance (1)  ·  Sirolimus (1)

Sponsors

Guangdong Second Provincial General Hospital (3)  ·  National Institute of Allergy and Infectious Diseases (NIAID) (3)  ·  First Affiliated Hospital of Zhejiang University (2)  ·  Michael Pulsipher (2)  ·  Autolus Limited (1)  ·  Bnai Zion Medical Center (1)  ·  Chinese PLA General Hospital (1)  ·  Landspitali University Hospital (1)  ·  National Institute of Pediatrics, Mexico (1)  ·  Paul Szabolcs (1)  ·  Phoenicia BioScience (1)  ·  Prime Medicine, Inc. (1)  ·  Ryvu Therapeutics SA (1)  ·  SWOG Cancer Research Network (1)  ·  Sanofi (1)

Countries

United States (12)  ·  China (8)  ·  Canada (3)  ·  France (3)  ·  Spain (3)  ·  Italy (2)  ·  Poland (2)  ·  United Kingdom (2)  ·  Armenia (1)  ·  Australia (1)  ·  Austria (1)  ·  Brazil (1)  ·  Bulgaria (1)  ·  Chile (1)  ·  Czechia (1)

Top investigators

Elizabeth M Kang, M.D. (2)  ·  Anjali S Advani (1)  ·  Guopan Yu, PhD (1)  ·  Hanny D Al-Samkari, MD (1)  ·  Kevin Kuo, MD (1)  ·  Michael L Pulsipher, MD (1)  ·  Michael Pulsipher, MD (1)  ·  Paul Szabolcs, MD (1)  ·  Sara Espinosa-Padilla, Ph.D. (1)  ·  Sigurdur Y Kristinsson, MD, PhD (1)  ·  Sujit Sheth, MD MS (1)  ·  Suk S De Ravin, M.D. (1)  ·  Susan Perrine, MD (1)  ·  Sylvia Singer, MD (1)

Results publications

PMID 11408503, PMID 11972517, PMID 14966830, PMID 15253677, PMID 17516870, PMID 17576459, PMID 19553647, PMID 21879172, PMID 23727426, PMID 23757085, PMID 24290319, PMID 24428625, PMID 24618152, PMID 24713845, PMID 25040088, PMID 25304690, PMID 25651996, PMID 26888258, PMID 28270698, PMID 28287336, PMID 28413626, PMID 28426102, PMID 28646338, PMID 29182564, PMID 29518185, PMID 30168576, PMID 31033786, PMID 31280227, PMID 31777071, PMID 31826366, PMID 35776909, PMID 39042892, PMID 41358590, PMID 9718381

NIH funding

2018 (1), 2023 (1), 2025 (1), R33HL147845 (1)